^
Association details:
| Biomarker: | IGH mutation |
|---|---|
| Cancer: | Small Lymphocytic Lymphoma |
| Regimen: | FCR (cyclophosphamide + fludarabine IV + Rituxan (rituximab)) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group
Published date:
02/22/2021
Excerpt:
The median progression-free survival was 29 months, but was markedly longer in patients with mutated IGHV (median 53 months)...Low-dose FCR is a well-tolerated and effective first-line regimen for selected elderly/comorbid patients with CLL/SLL with favourable biology.
DOI:
10.1111/bjh.17373
